Review



constant igg d  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    InvivoGen constant igg d
    A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of <t>full-length</t> <t>IgG</t> D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.
    Constant Igg D, supplied by InvivoGen, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/constant igg d/product/InvivoGen
    Average 91 stars, based on 1 article reviews
    constant igg d - by Bioz Stars, 2026-05
    91/100 stars

    Images

    1) Product Images from "Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors"

    Article Title: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

    Journal: mAbs

    doi: 10.1080/19420862.2023.2287250

    A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of full-length IgG D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.
    Figure Legend Snippet: A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of full-length IgG D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.

    Techniques Used: Binding Assay, Flow Cytometry, Clone Assay, Negative Control, Staining

    Full-length IgG D P3C6mut3.1 reverses the effects of PD-L1 inhibition on canine CAR-T cells. A. K562 cells were engineered to express canine CD20 (K562-cCD20) and canine PD-L1 (K562-cCD20-cPD-L1) and cell surface expression was confirmed by flow cytometry. B. Canine CD20 CAR-T cells from one dog were labeled with cell trace violet (CTV) and co-cultured at an E:T ratio of 1:1 with either K562-cCD20 or K562-cCD20-cPD-L1 in the presence of either anti-MERS or P3C6mut3.1 IgG D . After 72 hours of culture, proliferation of CD8 + CAR-T cells was assessed by flow cytometry. Plots are gated on live CD5 + CD8 + CAR + cells. C. Canine CD20 CAR-T cells from one dog were co-cultured at an E:T ratio of 1:1 with the same target cells as in A. Expression of CD107b was determined after 4 hours of co-culture. Plots are gated on live CD5 + CD8 + CAR + cells.
    Figure Legend Snippet: Full-length IgG D P3C6mut3.1 reverses the effects of PD-L1 inhibition on canine CAR-T cells. A. K562 cells were engineered to express canine CD20 (K562-cCD20) and canine PD-L1 (K562-cCD20-cPD-L1) and cell surface expression was confirmed by flow cytometry. B. Canine CD20 CAR-T cells from one dog were labeled with cell trace violet (CTV) and co-cultured at an E:T ratio of 1:1 with either K562-cCD20 or K562-cCD20-cPD-L1 in the presence of either anti-MERS or P3C6mut3.1 IgG D . After 72 hours of culture, proliferation of CD8 + CAR-T cells was assessed by flow cytometry. Plots are gated on live CD5 + CD8 + CAR + cells. C. Canine CD20 CAR-T cells from one dog were co-cultured at an E:T ratio of 1:1 with the same target cells as in A. Expression of CD107b was determined after 4 hours of co-culture. Plots are gated on live CD5 + CD8 + CAR + cells.

    Techniques Used: Inhibition, Expressing, Flow Cytometry, Labeling, Cell Culture, Co-Culture Assay

    Pharmacokinetics of full-length IgG D/B P3C6mut3.1 in healthy dogs. Healthy dogs were administered P3C6mut3.1 IgG D/B intravenously at either 2 mg/kg ( n = 2) or 10 mg/kg ( n = 2) on Day 0 and Day 21. Blood samples were taken at the indicated time points and analyzed for the presence of P3C6mut3.1 IgG D/B in the serum using a custom Meso Scale Discovery immunoassay. A. Serum pharmacokinetics of P3C6mut3.1 IgG D/B with data represented as mean ± SD. B. Dose-normalized concentration vs. time profiles for P3C6mut3.1 IgG D/B .
    Figure Legend Snippet: Pharmacokinetics of full-length IgG D/B P3C6mut3.1 in healthy dogs. Healthy dogs were administered P3C6mut3.1 IgG D/B intravenously at either 2 mg/kg ( n = 2) or 10 mg/kg ( n = 2) on Day 0 and Day 21. Blood samples were taken at the indicated time points and analyzed for the presence of P3C6mut3.1 IgG D/B in the serum using a custom Meso Scale Discovery immunoassay. A. Serum pharmacokinetics of P3C6mut3.1 IgG D/B with data represented as mean ± SD. B. Dose-normalized concentration vs. time profiles for P3C6mut3.1 IgG D/B .

    Techniques Used: Concentration Assay

    A non-compartmental analysis of full-length P3C6mut3.1 IgG D/B PK parameters following the first dose. C max : maximum observed serum concentration, AUC last : area under the serum concentration vs. time curve from time 0 to 21 days, AUC inf : area under the serum concentration vs. time curve extrapolated to time infinity, t 1/2 : terminal log-linear half-life, CL: clearance, V ss : volume of distribution.
    Figure Legend Snippet: A non-compartmental analysis of full-length P3C6mut3.1 IgG D/B PK parameters following the first dose. C max : maximum observed serum concentration, AUC last : area under the serum concentration vs. time curve from time 0 to 21 days, AUC inf : area under the serum concentration vs. time curve extrapolated to time infinity, t 1/2 : terminal log-linear half-life, CL: clearance, V ss : volume of distribution.

    Techniques Used: Concentration Assay



    Similar Products

    constant igg d  (InvivoGen)
    91
    InvivoGen constant igg d
    A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of <t>full-length</t> <t>IgG</t> D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.
    Constant Igg D, supplied by InvivoGen, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/constant igg d/product/InvivoGen
    Average 91 stars, based on 1 article reviews
    constant igg d - by Bioz Stars, 2026-05
    91/100 stars
    		  Buy from Supplier
    pfuse-higg1-fc2  (InvivoGen)
    95
    InvivoGen pfuse-higg1-fc2
    A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of <t>full-length</t> <t>IgG</t> D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.
    Pfuse Higg1 Fc2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pfuse-higg1-fc2/product/InvivoGen
    Average 95 stars, based on 1 article reviews
    pfuse-higg1-fc2 - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of full-length IgG D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.

    Journal: mAbs

    Article Title: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

    doi: 10.1080/19420862.2023.2287250

    Figure Lengend Snippet: A. Primary structures of lead canine anti-cPD-1 antibodies. A. (top) heavy chain alignments of P4B1, P3C6 and its variants along with canine germline gene IGHV3-38*01. (bottom) light chain alignments of P4B1 and P3C6. Framework and CDR regions use IMGT nomenclature. B. Evaluation of full-length IgG D (P3C6mut3.1 and mut3.2) canine anti-cPD-1 binding to cell surface-expressed cPD-1 by flow cytometry. Canine IgG D -HA tagged clones against cPD-1 or the irrelevant MERS antigen (negative control) were used to stain KTδ32 and KTδ32.cPD-1 cells. Bound IgG D molecules were detected using an anti-HA antibody. Plots are gated on live, 7AAD- cells.

    Article Snippet: The VH and VL chains of selected scFvs were cloned into separate expression plasmids engineered to express either canine constant light kappa (InvivoGen, pfuse2-dclk), constant light lambda (InvivoGen, pfuse2-dcll), or constant IgG D (analogous to human IgG4) heavy-chain domain (InvivoGen, pfuse-dchg4).

    Techniques: Binding Assay, Flow Cytometry, Clone Assay, Negative Control, Staining

    Full-length IgG D P3C6mut3.1 reverses the effects of PD-L1 inhibition on canine CAR-T cells. A. K562 cells were engineered to express canine CD20 (K562-cCD20) and canine PD-L1 (K562-cCD20-cPD-L1) and cell surface expression was confirmed by flow cytometry. B. Canine CD20 CAR-T cells from one dog were labeled with cell trace violet (CTV) and co-cultured at an E:T ratio of 1:1 with either K562-cCD20 or K562-cCD20-cPD-L1 in the presence of either anti-MERS or P3C6mut3.1 IgG D . After 72 hours of culture, proliferation of CD8 + CAR-T cells was assessed by flow cytometry. Plots are gated on live CD5 + CD8 + CAR + cells. C. Canine CD20 CAR-T cells from one dog were co-cultured at an E:T ratio of 1:1 with the same target cells as in A. Expression of CD107b was determined after 4 hours of co-culture. Plots are gated on live CD5 + CD8 + CAR + cells.

    Journal: mAbs

    Article Title: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

    doi: 10.1080/19420862.2023.2287250

    Figure Lengend Snippet: Full-length IgG D P3C6mut3.1 reverses the effects of PD-L1 inhibition on canine CAR-T cells. A. K562 cells were engineered to express canine CD20 (K562-cCD20) and canine PD-L1 (K562-cCD20-cPD-L1) and cell surface expression was confirmed by flow cytometry. B. Canine CD20 CAR-T cells from one dog were labeled with cell trace violet (CTV) and co-cultured at an E:T ratio of 1:1 with either K562-cCD20 or K562-cCD20-cPD-L1 in the presence of either anti-MERS or P3C6mut3.1 IgG D . After 72 hours of culture, proliferation of CD8 + CAR-T cells was assessed by flow cytometry. Plots are gated on live CD5 + CD8 + CAR + cells. C. Canine CD20 CAR-T cells from one dog were co-cultured at an E:T ratio of 1:1 with the same target cells as in A. Expression of CD107b was determined after 4 hours of co-culture. Plots are gated on live CD5 + CD8 + CAR + cells.

    Article Snippet: The VH and VL chains of selected scFvs were cloned into separate expression plasmids engineered to express either canine constant light kappa (InvivoGen, pfuse2-dclk), constant light lambda (InvivoGen, pfuse2-dcll), or constant IgG D (analogous to human IgG4) heavy-chain domain (InvivoGen, pfuse-dchg4).

    Techniques: Inhibition, Expressing, Flow Cytometry, Labeling, Cell Culture, Co-Culture Assay

    Pharmacokinetics of full-length IgG D/B P3C6mut3.1 in healthy dogs. Healthy dogs were administered P3C6mut3.1 IgG D/B intravenously at either 2 mg/kg ( n = 2) or 10 mg/kg ( n = 2) on Day 0 and Day 21. Blood samples were taken at the indicated time points and analyzed for the presence of P3C6mut3.1 IgG D/B in the serum using a custom Meso Scale Discovery immunoassay. A. Serum pharmacokinetics of P3C6mut3.1 IgG D/B with data represented as mean ± SD. B. Dose-normalized concentration vs. time profiles for P3C6mut3.1 IgG D/B .

    Journal: mAbs

    Article Title: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

    doi: 10.1080/19420862.2023.2287250

    Figure Lengend Snippet: Pharmacokinetics of full-length IgG D/B P3C6mut3.1 in healthy dogs. Healthy dogs were administered P3C6mut3.1 IgG D/B intravenously at either 2 mg/kg ( n = 2) or 10 mg/kg ( n = 2) on Day 0 and Day 21. Blood samples were taken at the indicated time points and analyzed for the presence of P3C6mut3.1 IgG D/B in the serum using a custom Meso Scale Discovery immunoassay. A. Serum pharmacokinetics of P3C6mut3.1 IgG D/B with data represented as mean ± SD. B. Dose-normalized concentration vs. time profiles for P3C6mut3.1 IgG D/B .

    Article Snippet: The VH and VL chains of selected scFvs were cloned into separate expression plasmids engineered to express either canine constant light kappa (InvivoGen, pfuse2-dclk), constant light lambda (InvivoGen, pfuse2-dcll), or constant IgG D (analogous to human IgG4) heavy-chain domain (InvivoGen, pfuse-dchg4).

    Techniques: Concentration Assay

    A non-compartmental analysis of full-length P3C6mut3.1 IgG D/B PK parameters following the first dose. C max : maximum observed serum concentration, AUC last : area under the serum concentration vs. time curve from time 0 to 21 days, AUC inf : area under the serum concentration vs. time curve extrapolated to time infinity, t 1/2 : terminal log-linear half-life, CL: clearance, V ss : volume of distribution.

    Journal: mAbs

    Article Title: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

    doi: 10.1080/19420862.2023.2287250

    Figure Lengend Snippet: A non-compartmental analysis of full-length P3C6mut3.1 IgG D/B PK parameters following the first dose. C max : maximum observed serum concentration, AUC last : area under the serum concentration vs. time curve from time 0 to 21 days, AUC inf : area under the serum concentration vs. time curve extrapolated to time infinity, t 1/2 : terminal log-linear half-life, CL: clearance, V ss : volume of distribution.

    Article Snippet: The VH and VL chains of selected scFvs were cloned into separate expression plasmids engineered to express either canine constant light kappa (InvivoGen, pfuse2-dclk), constant light lambda (InvivoGen, pfuse2-dcll), or constant IgG D (analogous to human IgG4) heavy-chain domain (InvivoGen, pfuse-dchg4).

    Techniques: Concentration Assay